Nektar Therapeutics (NKTR – Free Report) reported $29.18 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 22.1%. EPS of -$0.15 for the same period compares to -$0.22 a year ago.
The reported revenue represents a surprise of -25.23% over the Zacks Consensus Estimate of $39.02 million. With the consensus EPS estimate being -$0.13, the EPS surprise was -15.38%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company’s financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock’s price performance.
Here is how Nektar performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product sales: $12.87 million versus $9.76 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +134.8% change.
- Revenue- Non-cash royalty revenue related to sale of future royalties: $16.24 million compared to the $15.15 million average estimate based on eight analysts. The reported number represents a change of -10.1% year over year.
- Revenue- License, collaboration and other revenue: $0.06 million versus $28.26 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -81.5% change.
View all Key Company Metrics for Nektar here>>>
Shares of Nektar have returned +23.5% over the past month versus the Zacks S&P 500 composite’s -8.2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Financial Market Newsflash
No financial news published today. Check back later.
